Biotechnology Development

 

Micropoint biotechnology R&D leverages strong collaboration with groups of researchers and scientists around the world to develop novel biomarkers and antibodies that are customized to meet the rapid diagnostic needs. These co-development programs encompass sets/libraries of bio-marker screening, cell line engineering, protein expression, and bio-processing.

 

Micropoint works with its partners to develop novel bio-markers and antibodies with high affinity and high specificity in each of the following stages:

 

  • Hybridoma development

  • Polyclonal antibody

  • Antibody purification

  • Antibody Fragmentation and isotyping

  • Conjugation and labeling

  • Immune response testing

  • Novel assay development

  • Bio-signal amplifications

     

English

中文

Register Product

  • About

  • mLabs Platform

  • qLabs Handheld Platform

  • Technology

  • Clinical Applications

  • Education

  • Patients

  • More...

    About
    mLabs Platform
    qLabs Handheld Platform
    Technology
    Careers
    Contact
    External Resources
    Facilities
     
     
     

     

     

    U.S. Headquarters

     

    Micropoint Bioscience, Inc.
    3521 Leonard Court 
    Santa Clara, CA 95054
    United States

     

    T:+1 (408) 588-1682
    F:+1 (408) 588-1620

     

     

    European Office

     

    Micropoint Bioscience, Inc.

    2 rue Eugene Sue

    38100 Grenoble

    France 

     

    T: +33 6 22 38 20 48

    F: +33 4 76 09 03 50

    Asian Office

     

    Micropoint Biotechnologies Co., Ltd.

    5F, Bldg 1

    Runheng Dingfeng Industrial Park, Liuxian 2 Rd.

    Shenzhen 518101, Guangdong

    China

     

    T: +86 755 21600849

    F: +86 755 86673903

    Distributor Log-In
    Register Product

    Copyright Micropoint Biosciences 2016

    Micropoint Bioscience products are not available for sale nor marketed in the United States at this time.

    China FDA logo.JPG